Sarah Bray

2.4k total citations
29 papers, 874 citations indexed

About

Sarah Bray is a scholar working on Surgery, Oncology and Economics and Econometrics. According to data from OpenAlex, Sarah Bray has authored 29 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 8 papers in Oncology and 7 papers in Economics and Econometrics. Recurrent topics in Sarah Bray's work include Lipoproteins and Cardiovascular Health (12 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Sarah Bray is often cited by papers focused on Lipoproteins and Cardiovascular Health (12 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Sarah Bray collaborates with scholars based in United Kingdom, United States and Switzerland. Sarah Bray's co-authors include Hedy L. Kindler, Charles S. Fuchs, Adolfo Díez‐Pérez, Michael R. McClung, Stefan Goemaere, Jacques P. Brown, John Caminis, Andreas Grauer, Henry G. Bone and Judy Maddox and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Sarah Bray

28 papers receiving 863 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah Bray United Kingdom	14	315	311	276	131	129	29	874
Bettina S. Nedergaard Denmark	9	444 1.4×	341 1.1×	171 0.6×	97 0.7×	179 1.4×	13	960
Francesca Del Monte Italy	17	101 0.3×	458 1.5×	306 1.1×	77 0.6×	143 1.1×	27	1.0k
Anne Irene Hagen Norway	16	129 0.4×	564 1.8×	178 0.6×	411 3.1×	131 1.0×	31	1.2k
Mahesh Parmar United Kingdom	9	612 1.9×	357 1.1×	165 0.6×	172 1.3×	13 0.1×	12	1.5k
Damon Disch United States	10	68 0.2×	544 1.7×	235 0.9×	191 1.5×	328 2.5×	17	1.1k
John W. Kunstman United States	17	613 1.9×	518 1.7×	263 1.0×	168 1.3×	13 0.1×	43	1.3k
Maria Cossu Rocca Italy	18	237 0.8×	435 1.4×	149 0.5×	150 1.1×	40 0.3×	70	949
Mustafa Al-Mubarak Canada	7	149 0.5×	747 2.4×	212 0.8×	397 3.0×	17 0.1×	13	1.1k
Shigeto Maeda Japan	18	299 0.9×	535 1.7×	536 1.9×	183 1.4×	27 0.2×	63	1.5k
Sven Gogov Switzerland	12	36 0.1×	351 1.1×	294 1.1×	145 1.1×	24 0.2×	25	804

Countries citing papers authored by Sarah Bray

Since Specialization

Citations

This map shows the geographic impact of Sarah Bray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Bray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Bray more than expected).

Fields of papers citing papers by Sarah Bray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Bray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Bray. The network helps show where Sarah Bray may publish in the future.

Co-authorship network of co-authors of Sarah Bray

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Bray. A scholar is included among the top collaborators of Sarah Bray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Bray. Sarah Bray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Specks, Ulrich, Robert Spiera, Lynn A. Fussner, et al.. (2025). Treatment With Avacopan in Patients With Respiratory Tract Manifestations of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. ACR Open Rheumatology. 7(1). e11795–e11795. 4 indexed citations

Geetha, Duvuru, Thomas Neumann, Alexandre Karras, et al.. (2025). Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide. RMD Open. 11(4). e005743–e005743.

Geetha, Duvuru, Christian Pagnoux, Sebastian E. Sattui, et al.. (2025). Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial. Lara D. Veeken. 64(6). 3863–3871. 3 indexed citations

Sen, Siddhartha, Alec Victorsen, Todd P. Knutson, et al.. (2025). Validation of a comprehensive long-read sequencing platform for broad clinical genetic diagnosis. Frontiers in Genetics. 16. 1499456–1499456. 1 indexed citations

Brandts, Julia, Sarah Bray, Guillermo Villa, et al.. (2023). Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study. The Lancet Regional Health - Europe. 31. 100665–100665. 18 indexed citations

Tóth, Peter P., et al.. (2022). Network Meta‐Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid‐Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low‐Density Lipoprotein Cholesterol. Journal of the American Heart Association. 11(18). e025551–e025551. 30 indexed citations

Vráblík, Michal, Bohumil Seifert, Alexander Parkhomenko, et al.. (2021). Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis. 334. 66–75. 42 indexed citations

Santos, Raúl D., Evan A. Stein, G. Kees Hovingh, et al.. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the American College of Cardiology. 75(6). 565–574. 118 indexed citations

Boccara, Franck, Princy Kumar, Bruno Caramelli, et al.. (2020). EVOLOCUMAB USE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS AND DYSLIPIDEMIA: PRIMARY RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (BEIJERINCK). Journal of the American College of Cardiology. 75(11). 1832–1832. 5 indexed citations

10.

Santos, Raúl D., G. Kees Hovingh, Dirk Blom, et al.. (2019). LONG-TERM EVOLOCUMAB USE IN SUBJECTS WITH HOMOZYGOUS AND SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: PRIMARY RESULTS OF THE TAUSSIG TRIAL. Journal of the American College of Cardiology. 73(9). 1715–1715. 3 indexed citations

11.

Boccara, Franck, Princy Kumar, Bruno Caramelli, et al.. (2019). Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. American Heart Journal. 220. 203–212. 3 indexed citations

12.

McClung, Michael R., Jacques P. Brown, Adolfo Díez‐Pérez, et al.. (2018). Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. Journal of Bone and Mineral Research. 33(8). 1397–1406. 159 indexed citations

13.

Berre, Mélanie Le, et al.. (2016). The Psychometric Properties of a Modified Sit-to-Stand Test With Use of the Upper Extremities in Institutionalized Older Adults. Perceptual and Motor Skills. 123(1). 138–152. 13 indexed citations

14.

Sabin, Tony, James Matcham, Sarah Bray, Andrew Copas, & Mahesh Parmar. (2013). A Quantitative Process for Enhancing End of Phase 2 Decisions. Statistics in Biopharmaceutical Research. 6(1). 67–77. 18 indexed citations

15.

Demetri, George D., Axel Le Cesne, Sant P. Chawla, et al.. (2012). First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study. European Journal of Cancer. 48(4). 547–563. 53 indexed citations

16.

Kindler, Hedy L., Donald Richards, Lawrence Garbo, et al.. (2012). A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology. 23(11). 2834–2842. 157 indexed citations

17.

Cella, David, Zeeshan Butt, Hedy L. Kindler, et al.. (2012). Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Quality of Life Research. 22(5). 1105–1112. 46 indexed citations

18.

Allen, Andrew S., Glen A. Satten, Sarah Bray, Frank Dudbridge, & Michael P. Epstein. (2010). Fast and Robust Association Tests for Untyped SNPs in Case-Control Studies. Human Heredity. 70(3). 167–176. 3 indexed citations

19.

Kindler, Hedy L., Donald Richards, John Stephenson, et al.. (2010). A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 28(15_suppl). 4035–4035. 26 indexed citations

20.

O’Connor, Marie, Isabelle I. Salles, Ana Cvejic, et al.. (2008). Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood. 113(19). 4754–4762. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact